secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-039248
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics extends cash runway into 2027; will require partner for zerlasiran Phase 3
--------------------------------------------------------------------------------

- Net loss of $45.3M ($0.33 per share) for FY2024, compared to $54.2M loss in FY2023.
- Cash, cash equivalents and short-term investments of $147.3M at Dec 31, 2024.
- Collaboration revenue $43.1M (up $12.2M YoY); R&D expenses $67.9M (up $11M).
- Zerlasiran Phase 3 CVOT will not start without a partner; cash guidance extended into 2027.
- Divesiran Phase 2 PV enrollment expected to complete by end-2025; Hansoh Pharma exited collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525039248/0001193125-25-039248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525039248/d925669d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-039248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer